Related Experiment Video
Updated: Jan 28, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Impact of Proton Pump Inhibitor Use on Outcomes Following Carotid Artery Stenting for Asymptomatic Carotid Stenosis:
Chia-En Wong1,2, Pang-Shuo Perng1, Pei-Wen Chen3
1Division of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Abstract:
Carotid artery stenting (CAS) is an effective treatment for carotid stenosis. Proton-pump inhibitors (PPIs) are commonly prescribed in the general population. However, the impact of PPI use on outcomes following CAS remains unknown. This study investigated the impact of PPI use on CAS using a retrospective, matched-cohort analysis from the TriNetX research network. Propensity score matching (PSM) was employed to create two balanced cohorts consisting of regular PPI users and nonusers who underwent CAS for asymptomatic carotid stenosis. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using the TriNetX platform to compare cerebrovascular and cardiovascular outcomes. A total of 20,153 patients were included. After PSM, 4691 patients were included in both the PPI and non-PPI cohorts. The mean age at the time of CAS was 70.4 years in both groups. Compared with non-PPI users, patients in the PPI cohort had a higher incidence of 30-day periprocedural stroke (OR: 1.35; 95% CI: 1.08-1.69; p = 0.009). Analyses of 2-year outcomes demonstrated that regular PPI users had a higher incidence of ischemic stroke (OR: 1.16; 95% CI: 1.01-1.32; p = 0.034), transient ischemic attack (TIA) (OR: 1.30; 95% CI: 1.14-1.49; p < 0.001), and myocardial infarction (OR: 1.19; 95% CI: 1.03-1.38; p = 0.018) compared with non-PPI users. In patients undergoing CAS for asymptomatic carotid stenosis, PPI use was associated with an increased risk of periprocedural stroke, as well as a higher incidence of ischemic stroke, TIA, and myocardial infarction over a 2-year follow-up period.
More Related Videos
09:36A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis
Published on: August 12, 2025
08:41Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
What is Population Genetics?
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
ATP Driven Pumps III: V-type Pumps
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
ATP Driven Pumps II: P-type Pumps
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...